|
Run Up
May 28, 2014 15:53:28 GMT -5
Post by biotec on May 28, 2014 15:53:28 GMT -5
Looks like the run up has started, Broke $8.00. Hate to be a short at this time!
|
|
|
Post by seanismorris on May 31, 2014 1:20:16 GMT -5
Off topic...
I performed my regular search on Google tonight (12:10AM, May 31st) for Afrezza (restricted to the last 24 hours) and the 2nd and 3rd results were:
Eli Lilly and Company newsroom.lilly.com/ 6 hours ago - Welcome to the Lilly Newsroom, where you can find the latest stories and headlines affecting Eli Lilly and Company and the pharmaceutical industry.
Sanofi - Investors - Ensuring sustainable growth en.sanofi.com/investors/investors.aspx 9 hours ago - Sanofi - A diversified healthcare company, focused on patients' needs.
Does the results make you go hmmm...
(News posted but not released?)
|
|
|
Run Up
May 31, 2014 9:23:14 GMT -5
Post by MnkdMainer (MM) on May 31, 2014 9:23:14 GMT -5
Any idea why Sanofi and Lilly appear in these results? I duplicated your search and verified the results. But when I searched for Afrezza, Mannkind, and mnkd on the results pages, I found nothing. Anyone?
|
|
|
Post by notamnkdmillionaire on May 31, 2014 10:12:27 GMT -5
Any idea why Sanofi and Lilly appear in these results? I duplicated your search and verified the results. But when I searched for Afrezza, Mannkind, and mnkd on the results pages, I found nothing. Anyone? I have seen the results too and from my understanding each company has an internal internet that might mention Afrezza but is not for public consumption. Google might catch this but won't publicly show the intranet result. Again, that is how it was explained to me. In the end, it most likely means nothing.
|
|
|
Run Up
May 31, 2014 10:56:03 GMT -5
Post by thekindaguyiyam on May 31, 2014 10:56:03 GMT -5
from Schaeffer's Options Center 5/30/14 MannKind Corporation (NASDAQ:MNKD) tagged a new high of $9.46 earlier today, its highest point since January 2011. At last check, the shares were still sitting pretty, up 3.7% at $8.86. Despite its move to new highs, MNKD has been targeted by put traders today. In fact, put volume is running at 10 times the typical pace, with the heaviest attention focused on the out-of-the-money August 7 strike. Implied volatility (IV) has spiked at this strike, the majority of the puts have crossed on the ask side, and volume exceeds open interest, suggesting the puts are being purchased to open. Given the stock's year-to-date rally of nearly 71%, however, it's possible some of these out-of-the-money bets are the work of shareholders looking to protect their pre-existing stock position. Whatever the motive, it's a good time to purchase MNKD options premium. While the security's 30-day at-the-money (ATM) IV is up 18.3% at 81.3% today, its Schaeffer's Volatility Index (SVI) reading of 66% is just 2 percentage points shy of an annual low. In other words, short-term options are inexpensively priced, from a volatility perspective. www.schaeffersresearch.com/marketcenters/optionscenter/content/option+clips+mannkind+corporation+emc+corporation+and+infoblox+inc/default.aspx?ID=121303Also: from StreetInsider.com re: May 30th 52 week high MannKind Corp. (Nasdaq: MNKD) $9.46. MannKind looks to be squeezing higher Friday. About 29 percent of the company's stock is out on loan and the company will present at Jefferies Global Healthcare Conference next week. www.streetinsider.com/Special+Reports/Notable+52-Week+Highs+and+Lows+of+the+Day+0530%3A+(OVTI)+(MNKD)+(BIG)+High%3B+(BLOX)+(SPLK)+(PSUN)+Low/9539100.html
|
|
|
Run Up
May 31, 2014 11:37:27 GMT -5
Post by seanismorris on May 31, 2014 11:37:27 GMT -5
It's impossible to know what the Google results mean...
Google probably detected some documents that are only accessible from their internal network (requires a log in to become visible). Found META data.
It could be an internal marketing study comparing Afrezza to their own products (though it is interesting that they are located in the newsroom)
It could be one company buying Mannkind and Afrezza, and partnering with another to develope other Technosphere formulations (this would be a nice scenario because MNKD could be purchased for more than we'd expect)
It could be both companies doing do diligence as potential partners for Afrezza (very likely, because both are two of the four big players in Diabetes).
It could be Mannkind sent both companies a copy of the Afrezza marketing study (showing docs willingness to prescribe Afrezza to patients)
It could mean anything....but we do know two biggies are interested or concerned about Afrezzas potential (but that's expected).
I'd only be concerned, if I was short MNKD because I believed Mannkind was lying about the multiple potential Afrezza partners.
Sanofi and Eli Lilly get a slight bump up (in my book), as likely partners for Afrezza.
|
|